{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:35Z","timestamp":1787028635716,"version":"build-2736575974"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Invasive lobular carcinoma accounts for 10 to 15% of all breast cancers. The first objective of this retrospective study was to assess the diagnostic performance of FDG-PET\/CT scanning in women previously treated for invasive lobular carcinoma with suspected first recurrence. The secondary objectives were to evaluate the impact of PET\/CT in a change in treatment and its prognostic value on specific survival. Methods: Patients in whom a PET\/CT scan was performed from January 2011 to July 2019 in our Cancer Research Center were enrolled. Recurrence was suspected based on clinical symptoms, abnormal findings on conventional imaging, and\/or elevated tumor markers. The diagnosis of recurrence was established by the oncologist after integration of all clinical, biological, histological, imaging, and follow-up data. Prognostic factors of recurrence as predicted by PET were determined using univariate logistic regression. KI67, mitotic index, or grade of mitosis were tested. Survival curves were compared using the log-rank test. Sixty-four patients (mean age: 60.3; SD = 12.4 years) were enrolled. The average time from initial diagnosis of the primary tumor to suspicion of recurrence was 5.2 \u00b1 4.1 years. Forty-eight patients (75%) were judged to have recurrence by the oncologist: 7 local and 41 metastatic, with mainly bone (n = 24), lymph node (n = 14) and liver (n = 10) metastases. Results: Sensitivity, specificity, and positive and negative predictive values of PET\/CT to predict recurrence were, respectively: 87%, 87%, 95%, and 70%. SUVmax at recurrence sites was generally high (mean: 6.4; SD = 2.9). False negative PET\/CT results occurred with local (n = 2), peritoneal (n = 2), meningeal (n = 1), or bladder (n = 1) recurrences. In 40 patients with available histopathological data from suspected sites of recurrence, 30 PET\/CT were true positive. In four patients, primary lung (n = 1) or gastric (n = 1) tumors or lymphomas (n = 2) were found. The detection of a recurrence resulted in a change in treatment in 44\/48 patients (92%). No association between recurrence predicted by PET and biological biomarkers was found. Median specific survival appears shorter in patients with metastatic recurrence versus patients with local or no recurrence on PET\/CT (p = 0.067). Conclusions: FDG-PET\/CT is an effective and reliable tool for the detection of invasive lobular carcinoma recurrence, although certain recurrence sites specific to this histological type can impair its diagnostic performance.<\/jats:p>","DOI":"10.3390\/jcm12082916","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T01:36:45Z","timestamp":1681781805000},"page":"2916","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Performance of [18F]FDG-PET\/CT Imaging in First Recurrence of Invasive Lobular Carcinoma"],"prefix":"10.3390","volume":"12","author":[{"given":"David","family":"Bonnin","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-9194","authenticated-orcid":false,"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Georges Francois Leclerc Research Cancer Center; 21000 Dijon, France"},{"name":"Research Center INSERM LNC-UMR1231, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Briot","sequence":"additional","affiliation":[{"name":"Department of Methodology and Biostatistics, Georges-Francois Leclerc Research Cancer Center, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-9509","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Bertaut","sequence":"additional","affiliation":[{"name":"Department of Methodology and Biostatistics, Georges-Francois Leclerc Research Cancer Center, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Drouet","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Cochet","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France"},{"name":"Laboratoire ICMUB, University Bourgogne, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Alberini","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France"},{"name":"Laboratoire ICMUB, University Bourgogne, 21000 Dijon, France"},{"name":"Centre Georges-Francois Leclerc, 1 rue du Pr Marion, 21079 Dijon CEDEX, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13058-015-0519-x","article-title":"Invasive lobular carcinoma of the breast: Morphology, biomarkers and \u2019omics","volume":"17","author":"Reed","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/1097-0142(20000601)88:11<2561::AID-CNCR19>3.0.CO;2-X","article-title":"Changing incidence rate of invasive lobular breast carcinoma among older women","volume":"88","author":"Li","year":"2000","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/sj.bjc.6602787","article-title":"Clinical characteristics of different histologic types of breast cancer","volume":"93","author":"Li","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/bjc.1984.135","article-title":"A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast","volume":"50","author":"Harris","year":"1984","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejca.2003.08.007","article-title":"Wide metastatic spreading in infiltrating lobular carcinoma of the breast","volume":"40","author":"Ferlicot","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1148\/rg.291085100","article-title":"Invasive lobular carcinoma of the breast: Spectrum of mammographic, US, and MR Imaging findings","volume":"29","author":"Lopez","year":"2009","journal-title":"RadioGraphics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s002590050319","article-title":"Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation","volume":"25","author":"Crippa","year":"1998","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_9","first-page":"9","article-title":"Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis","volume":"42","author":"Avril","year":"2001","journal-title":"J. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jjco\/hyn019","article-title":"Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography fusion imaging (18F-FDG-PET\/CT) in primary breast cancer","volume":"38","author":"Ueda","year":"2008","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/bjs.6459","article-title":"Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer","volume":"96","author":"Zornoza","year":"2009","journal-title":"Br. J. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","article-title":"Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer","volume":"38","author":"Groheux","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1007\/s00259-012-2211-z","article-title":"Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy","volume":"39","author":"Koolen","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00259-015-3110-x","article-title":"Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG-PET\/CT volumetric and heterogeneity features in stage II\/III breast cancer?","volume":"42","author":"Groheux","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12957-015-0522-9","article-title":"Associations between the standardized uptake value of 18F-FDG-PET\/CT and the prognostic factors of invasive lobular carcinoma: In comparison with invasive ductal carcinoma","volume":"13","author":"Jung","year":"2015","journal-title":"World J. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/PAS.0b013e3182918a2b","article-title":"Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry","volume":"37","author":"Dabbs","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2002.20.2.379","article-title":"Biologic correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by Positron Emission Tomography","volume":"20","author":"Bos","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2967\/jnumed.115.161455","article-title":"Comparison of 18F-FDG-PET\/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma","volume":"56","author":"Hogan","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/0284186X.2015.1054952","article-title":"Is 18F-FDG-PET\/CT an accurate tool for identifying metastases of lobular breast cancer?","volume":"55","author":"Orevi","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/bjc.1991.145","article-title":"A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast","volume":"63","author":"Dixon","year":"1991","journal-title":"Br. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jso.2930480106","article-title":"Metastatic pattern of infiltrating lobular carcinoma of the breast: An autopsy study","volume":"48","author":"Lamovec","year":"1991","journal-title":"J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/bcr767","article-title":"Infiltrating lobular carcinoma of the breast: Tumor characteristics and clinical outcome","volume":"6","author":"Arpino","year":"2004","journal-title":"Breast Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2214\/ajr.175.3.1750795","article-title":"Metastatic lobular carcinoma of the breast: Patterns of spread in the chest, abdomen, and pelvis on CT","volume":"175","author":"Winston","year":"2000","journal-title":"Am. J. Roentgenol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2214\/AJR.13.11156","article-title":"Distant metastatic disease manifestations in infiltrating lobular carcinoma of the breast","volume":"202","author":"He","year":"2014","journal-title":"Am. J. Roentgenol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/cncr.25727","article-title":"Breast cancer recurrence diagnosis suspected on tumor marker rising: Value of whole-body 18FDG-PET\/CT imaging and impact on patient management","volume":"117","author":"Champion","year":"2011","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s00259-015-3080-z","article-title":"Appearance of untreated bone metastases from breast cancer on FDG-PET\/CT: Importance of histologic subtype","volume":"42","author":"Dashevsky","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.2967\/jnumed.115.157859","article-title":"18F-FDG-PET\/CT for staging and restaging of breast cancer","volume":"57","author":"Groheux","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MNM.0000000000000768","article-title":"Clinical utility of 18F-FDG-PET\/CT in low 18F-FDG-avidity breast cancer subtypes: Comparison with breast US and MRI","volume":"39","author":"Park","year":"2018","journal-title":"Nucl. Med. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1470-7330-14-13","article-title":"The utility of 18F-FDG-PET\/CT for suspected recurrent breast cancer: Impact and prognostic stratification","volume":"14","author":"Cochet","year":"2014","journal-title":"Cancer Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4068\/cmj.2017.53.2.133","article-title":"Correlation of prognostic factors of invasive lobular carcinoma with ADC value of DWI and SUVMax of FDG-PET","volume":"53","author":"Choi","year":"2017","journal-title":"Chonnam Med. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2967\/jnumed.115.170456","article-title":"Initial results of a prospective clinical trial of 18F-Fluciclovine PET\/CT in newly diagnosed invasive ductal and invasive lobular breast cancers","volume":"57","author":"Ulaner","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2967\/jnumed.116.183335","article-title":"Prospective clinical trial of 18F-Fluciclovine PET\/CT for determining the response to neoadjuvant therapy in invasive ductal and invasive lobular breast cancers","volume":"58","author":"Ulaner","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2967\/jnumed.119.228858","article-title":"Recent advances in imaging steroid hormone receptors in breast cancer","volume":"61","author":"Kumar","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/RLU.0000000000001724","article-title":"18F-FES PET has added value in staging and therapy decision making in patients with disseminated lobular breast cancer","volume":"42","author":"Venema","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2967\/jnumed.120.247882","article-title":"Head-to-head evaluation of 18F-FES and 18F-FDG-PET\/CT in metastatic invasive lobular breast cancer","volume":"62","author":"Ulaner","year":"2021","journal-title":"J. Nucl. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/8\/2916\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:17:28Z","timestamp":1760123848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/8\/2916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12082916"],"URL":"https:\/\/doi.org\/10.3390\/jcm12082916","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]}}}